Innoviva Price to Free Cash Flow Ratio 2010-2024 | INVA

Historical price to free cash flow ratio values for Innoviva (INVA) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Innoviva Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-11-19 19.09 17.69
2024-09-30 19.31 $1.08 17.90
2024-06-30 16.40 $1.01 16.28
2023-12-31 16.04 $1.62 9.91
2023-09-30 12.99 $2.93 4.44
2023-06-30 12.73 $3.09 4.12
2023-03-31 11.25 $2.56 4.39
2022-12-31 13.25 $3.08 4.30
2024-03-31 15.24 $2.45 6.22
2022-09-30 11.61 $2.62 4.43
2022-06-30 14.76 $4.03 3.66
2022-03-31 19.35 $4.16 4.65
2021-12-31 17.25 $3.86 4.47
2021-09-30 16.71 $4.00 4.18
2021-06-30 13.41 $3.08 4.35
2021-03-31 11.95 $2.85 4.19
2020-12-31 12.39 $2.76 4.49
2020-09-30 10.45 $2.60 4.03
2020-06-30 13.98 $2.45 5.72
2020-03-31 11.76 $2.24 5.25
2019-12-31 14.16 $2.27 6.24
2019-09-30 10.54 $2.22 4.74
2019-06-30 14.56 $2.25 6.47
2019-03-31 14.03 $2.21 6.36
2018-12-31 17.45 $1.97 8.85
2018-09-30 15.24 $1.83 8.35
2018-06-30 13.80 $1.66 8.31
2018-03-31 16.67 $1.39 11.98
2017-12-31 14.19 $1.18 12.00
2017-09-30 14.12 $0.95 14.84
2017-06-30 12.80 $0.75 17.01
2017-03-31 13.83 $0.66 20.98
2016-12-31 10.70 $0.49 21.72
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.195B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03